RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Innocrin Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing small-molecule CYP17 lyase-selective inhibitors for the treatment of hormonally-dependent breast and prostate cancers resistant to traditional therapy, today announced the appointment of Charles (Chuck) Osborne, CPA as its Chief Financial Officer, effective July 1, 2015.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
